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Abstract 
Background: The relationship between violence and neurocognitive function in schizophrenia is unclear. We exam-
ined the backgrounds and neurocognitive functions of violent and nonviolent patients with schizophrenia to identify 
factors associated with serious violence.
Methods: Thirty male patients with schizophrenia who were hospitalized after committing serious violent acts were 
compared with 24 hospitalized male patients with schizophrenia and no history of violence. We evaluated psychiatric 
symptoms using the Positive and Negative Syndrome Scale (PANSS) and neurocognitive functions using the Brief 
Assessment of Cognition in Schizophrenia (BACS)-Japanese version.
Results: Repeated-measures analyses of variance on BACS subcomponents z-scores showed that the violent and 
control groups had different neuropsychological profiles at trend level (p = 0.095). Post hoc analyses of variance indi-
cated that the violent group had significantly better working memory and executive function than the control group. 
In post hoc ANOVAs also controlling for the effect of the presence of substance abuse on cognitive function, violent 
or nonviolent group had a significant main effect on executive function but not on working memory.
Conclusions: Patient with violent or non-violent schizophrenia have distinct neuropsychological profiles. These 
results may help develop improved psychosocial treatments.
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Background
The relationship between cognitive function and violence 
has been well documented [1, 2]. Non-psychotic subjects 
who exhibit repetitive antisocial or violent behaviors 
have deficits in language, memory, and executive func-
tion [3]. Impaired executive function was also observed 
in subjects who demonstrated repeated antisocial or 
violent behaviors without psychotic disorders, but who 
had psychiatric diagnoses including antisocial personal-
ity disorder, conduct disorder, and psychopathy [4]. Ser-
per et  al. suggested that individuals who have executive 
dysfunction display aggressive behavior because they 
struggle to cope with their deteriorating mental function-
ing or daily life stressors [5].
Among patients with schizophrenia, reported associa-
tions between neurocognitive performance and violence 
or aggression have been inconsistent [6, 7]. Some studies 
indicate that patients with schizophrenia who have a vio-
lent behavioral history perform better on tests of execu-
tive function than nonviolent patients [3, 8]. Although 
a nonviolent group was not assessed, Lapierre et  al. 
found that the number of serious violent acts correlated 
with higher executive function among outpatients with 
schizophrenia [9]. However, several studies reported no 
differences in neurocognitive functions (including execu-
tive function) between patients with schizophrenia and 
violent behavior, and those with schizophrenia but no 
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violent behavior [10–14]. In contrast, Barkataki et  al. 
found that compared with inpatients with schizophrenia 
and no violent history, forensic inpatients with schizo-
phrenia performed worse on executive function tests 
[15]. Moreover, in two reports, executive dysfunction 
was found to be a predictor of aggression in patients with 
schizophrenia, as measured by tools such as the Modified 
Overt Aggression Scale [5, 16]. These inconsistent find-
ings seem to be the result of differences in study method-
ologies, differences in the definitions of violent behavior, 
differences in the severity of the violence, differences in 
the study settings such as inpatient and outpatient, and 
differences in the heterogeneity of patient characteristics. 
Differences between violence that occurs in the com-
munity and that during hospitalization may also explain 
such inconsistencies.
To minimize heterogeneity among patients and their 
violent behavior, we examined hospitalized subjects with 
schizophrenia who had a history of serious physically 
violent behaviors (including murder, attempted murder, 
and inflicting serious injury), who were receiving treat-
ment under the Medical Treatment and Supervision Act 
(MTSA; also known as the Act for the Medical Treatment 
and Supervision of Persons with Mental Disorders who 
Caused Serious Harm). This relatively new legislative act 
focuses on offenders with mental disorders in Japan who 
are considered to be responsive to psychiatric treatment. 
It aims to promote rehabilitation among individuals who 
have committed serious harm to others (including homi-
cide, robbery, bodily injury, arson, or a sex crime) while 
in a state of insanity or diminished responsibility [17]. 
There were offenses that were committed deliberately 
due to hallucinations or delusions, but most of these were 
committed impulsively due to the influence of the hal-
lucinations or delusions. Offenses that were committed 
deliberately for practical reasons were not subject to the 
MTSA, even in cases of schizophrenia. Thus, we sampled 
subjects with relatively uniform psychotic symptoms and 
violent actions for the current study. We used the Brief 
Assessment of Cognition in Schizophrenia–Japanese 
Version (BACS-Japanese version) [18, 19] for neuropsy-
chological testing, which is sensitive to schizophrenia-
related cognitive deficits, and has been suggested to 
correlate with functional outcome.
As we considered the enactment of serious violence, 
even if under the influence of the hallucinations or the 
delusions associated with impulsion, to require some 
degree of executive function (e.g., planning ability), 
we hypothesized that patients with schizophrenia who 
exhibit serious violent behavior while experiencing psy-
chotic symptoms would perform no worse on neurocog-
nitive tests (including those of executive function) than 
nonviolent patients. To explore these hypotheses, we 
investigated differences among carefully controlled vio-
lent and nonviolent patient groups.
Methods
Ethical statement
This study was approved by the Ethical Review Board of 
the National Center of Neurology and Psychiatry. All par-
ticipants were given a complete description of the study 
and provided written informed consent.
Participants
Participants in the violent group were patients hos-
pitalized in the forensic unit of the National Center of 
Neurology and Psychiatry Hospital in Japan under the 
MTSA. Each patient met the following criteria: (1) had 
a diagnosis of schizophrenia according to the Diagnos-
tic and Statistical Manual of Mental Disorders, Fourth 
Edition, Text Revision (DSM-IV-TR) [20]; (2) was aged 
between 20 and 65  years; (3) had no organic disorder 
(e.g., complications such as tumors and other space-
occupying lesions in the brain, cerebrovascular disor-
ders, encephalitis, and epilepsy); (4) had committed 
murder, attempted murder, or caused serious injury 
to others (the relevant action) in a state of insanity or 
diminished responsibility; and, (5) was capable of par-
ticipating in the study, as determined by a multidiscipli-
nary treatment-team evaluation. We excluded women 
from this study because only two female patients met 
the study criteria; their relevant actions were attempted 
murder and serious injury.
Among the 53 males diagnosed with schizophrenia and 
hospitalized between September 2011 and May 2013, 
we selected 41 patients as violent group candidates. All 
selected had committed murder, attempted murder, or 
caused injury to others. Of the 41 patients, two were 
excluded because they were in the observation stage; eth-
ical guidelines do not allow research participation during 
this stage. Six selectees were excluded by the multidisci-
plinary team to avoid potential patient-staff conflicts, and 
three refused to participate (not due to psychiatric symp-
toms). The final sample consisted of 30 violent group par-
ticipants. Among these participants, 16 had caused injury 
to others, five had committed murder, and nine had 
attempted murder. Eight of the violent group participants 
had a history of substance abuse: four were alcohol abuse, 
3 were cannabis, and the other used multiple substances 
including amphetamines and cannabis. Of the 8 violent 
cases with substance abuse, 4 had ingested alcohol at 
the time of the relevant action. One was using synthetic 
cannabis. The duration of substance abuse may have 
an effect on cognitive function, however, we could not 
obtain accurate duration of substance abuse for the sub-
jects of this study. It has been reported that comorbidity 
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with substance abuse contributes to an increase of vio-
lent risk among patients with schizophrenia [21]. So, 
we included the subjects with substance abuse in our 
analysis reported below. Participants were hospitalized 
for an average of 330 days (range 25–1061 days). All vio-
lent group participants scored either 3 or 4 for strength 
of relationship between the relevant action and psycho-
sis, according to the Coding Guide for Violent Incidents 
[22]. The high scores may have resulted from laws requir-
ing the presence of a treatable condition with a strong 
relationship between the serious crime and psychiat-
ric symptoms for patient hospitalization in a Japanese 
MTSA ward.
For the comparison group (referred to as the control 
group), we selected age- and gender-similar individuals 
from hospitalized patients in a closed general psychi-
atric ward of the same hospital (average length of stay: 
40  days) who met all other violent group criteria, but 
had no history of physical violence (with scores of ≤1 
on the Gunn and Robertson Scale for Violence [23]), or 
prior hospitalizations for harming others. Among the 35 
men hospitalized in the ward, we chose 24 for control 
group inclusion, who satisfied our selection criteria and 
matched the ages of those in the violent group. Three of 
the control-group participants had a history of substance 
abuse: two were cannabis, and the other was multiple 
substances, including an amphetamine, cannabis and 
alcohol. Participants were hospitalized for an average of 
18 days (range 1–105 days).
Procedures
We investigated age, years of education, age of onset, ill-
ness duration, history of substance abuse or dependence 
(excluding nicotine dependence), and violence or crimi-
nal records in the patients’ medical records and court 
files. At the time of BACS-Japanese version testing, we 
determined the type and dose of psychotropic drugs 
prescribed. For antipsychotics, we applied the chlor-
promazine conversion to estimate daily dosage [24]. For 
anti-Parkinson agents, we applied the biperiden conver-
sion [25]. For anxiolytic and hypnotic agents, we used 
the diazepam conversion [24], and summed the values 
as benzodiazepine equivalents. Symptom severity was 
assessed by trained psychiatrists using the positive and 
negative syndrome scale (PANSS) [26, 27].
Neuropsychological measures
To assess verbal memory, working memory (digit 
sequencing test), motor speed (token motor test), ver-
bal fluency, attention (symbol coding test), and executive 
function (Tower of London test), we used the BACS-Jap-
anese version, which was administered by well-trained 
psychologists.
Z-scores were calculated for each subcomponent score 
using means and standard deviations based on age and 
gender data from matched healthy-control Japanese pop-
ulations [28].
Data analyses
We conducted statistical analyses with SPSS software for 
Windows, version 20.0. To compare the violent and con-
trol groups in terms of general characteristics, we used 
the Mann–Whitney U-test. History of substance use dis-
order was compared between groups using Fisher’s exact 
test.
Each BACS-Japanese version subcomponent score was 
normally distributed, except for those measuring work-
ing memory, attention, and executive function. To mod-
ify each curve to a normal distribution, we performed a 
logarithmic transformation of these scores.
No general characteristics differed significantly 
between the violent and control groups. In previous stud-
ies, anticholinergic use [29] and the existence of sub-
stance abuse [30] were correlated with neurocognitive 
test performance in patients with schizophrenia. Thus, 
repeated measures analyses of variance were performed 
using the six BACS subcomponents z-scores as depend-
ent variables, “group” (violent or control) and “the pres-
ence of substance abuse” (11 subjects: yes; 43 subjects: 
no) as fixed inter-individual (between-subjects) factors, 
BACS subcomponents as an intra-individual (within-
subjects) factor with 6 levels, and anti-Parkinson drug 
dosage (biperiden equivalents) as a covariate. We used 
Greenhouse-Geisser values to correct for potential viola-
tions in the assumption of sphericity.
Post hoc analysis of variance on each BACS-Japanese 
version item was performed using anti-Parkinson drug 
dosage as a covariate whenever necessary. Significance 
levels were determined at p < 0.05.
Results
General characteristics of the violent and control groups 
of patients with schizophrenia are shown in Table  1. 
No main “group” effect (F [1, 49] = 0.008, p = 0.929) was 
found. The BACS subcomponents within-subjects fac-
tor was significant (F [2.976, 145.823]  =  9.941, p  <  0.001). 
The interaction between “group” and “subcomponent” 
was approaching significant (F [2.976, 145.823]  =  2.166, 
p = 0.095).
As this is an exploratory study, we conducted post hoc 
analyses for “group” that had a nearly significant interac-
tion with the subcomponents as stated above. As deter-
mined by post hoc analyses of variance, the violent group 
performed significantly better than the control group on 
BACS-Japanese-version measures of working memory 
and executive function (Table 2). To control the effect of 
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“the presence of substance abuse” on cognitive function, 
we performed the univariate analyses of variance on the 
BACS-Japanese version [EX] (−log[3-(Executive function 
BACS-J z-score)]) and [WO] (−log[6-(Working memory 
BACS-J z-score)]) using both “group” and “the pres-
ence of substance abuse” as factors and anti-Parkinson 
drug dosage as a covariate. As the results, main “group” 
effect on executive function was found (F [1, 49] = 6.915, 
p = 0.011), while main “group” effect on working mem-
ory was not found (F [1, 49] = 1.131, p = 0.293).
Discussion
Schizophrenia-related violence is diverse and includes 
cases that vary widely in severity. We carefully selected 
violent cases among hospitalized subjects treated under 
specialized legislation and investigated their neurocogni-
tive features using a comprehensive cognitive assessment 
scale (the BACS-Japanese version). There were no differ-
ences from the control group in length of education, age 
of illness onset, illness duration, drug dosage, or PANSS 
scores.
We found that, in comparison with the nonviolent 
group, patients with a history of serious violence tended 
to have better executive function than the non-violent 
patients. This result is consistent with previous work by 
Naudts and Hodgins [1], who reported that patients with 
schizophrenia and antisocial behavior or violence dem-
onstrated less executive function impairment than those 
without these behaviors. In contrast, Schug and Raine 
[2] concluded that patients with schizophrenia and anti-
social behavior were distinguishable from those without 
antisocial behavior by memory impairments, but not 
executive dysfunction.
Brain imaging studies have suggested that violence in 
patients with schizophrenia is associated with the amyg-
dala-orbitofrontal system [1], orbitofrontal cortex [31], 
temporal lobe [32], and hippocampus [33]. Naudts and 
Hodgins have suggested that, compared with controls, 
Table 1 General characteristics of the violent and control groups
a n = 21 (three subjects were not available.)
Violent Control U p
(n = 30) (n = 24)
Mean (SD) Mean (SD)
Age 44.1 (11.5) 40.3 (10.7) 297 0.273
 Years of education 13.1 (2.6) 14.3 (2.8) 279 0.151
 Age of onset (years) 25.7 (6.9) 24.4 (7.3) 308 0.360
 Duration of illness (years) 18.0 (12.6) 15.9 (11.8) 319 0.470
Mean dosage of antipsychotics
 Chlorpromazine equivalent dosage (mg/day) 845.63 (528.22) 725.77 (391.29) 325 0.541
 Mean dosage of anti-Parkinson drugs
 Biperiden equivalent dosage (mg/day) 0.66 (1.35) 0.88 (1.19) 310 0.294
Mean dosage of benzodiazepines
 Diazepam equivalent dosage (mg/day) 8.97 (12.56) 8.97 (8.61) 314 0.413
 PANSS positive score 17.03 (5.56) 16.95 (7.13)a 284 0.545
 negative score 20.20 (7.07) 18.38 (6.51)a 272 0.410
 general psychotic score 36.80 (9.95) 32.86 (11.51)a 232 0.114
 Substance abuse (yes:no) 8:22 3:21 0.310
Table 2 Violent and control group BACS-Japanese version 
score comparisons with post hoc analyses of variance
[WO] = −log[6-(Working memory BACS-J z-score)]
[AT] = −log[7-(Attention BACS-J z-score)]





F P Cohen’s d
(n = 30) (n = 24)
Mean (SD) Mean (SD)
Verbal 
memory
−1.83 (1.04) −2.01 (1.50) 0.205 0.653 0.14
Working 
memory
−0.94 (1.11) −1.80 (1.67)
[WO] −2.06 (0.15) −2.16 (0.18) 4.162 0.047 0.61
Motor speed −1.90 (1.13) −1.92 (1.72) 0.006 0.904 0.01
Verbal flu-
ency
−1.10 (1.13) −0.93 (1.53) 0.084 0.773 0.13
Attention −2.44 (1.14) −3.05 (1.59)
[AT] −2.34 (0.11) −2.40 (0.14) 2.090 0.154 0.48
Executive 
function
−0.60 (1.88) −2.98 (3.32)
[EX] −1.15 (0.55) −1.67 (0.48) 12.791 <0.001 1.00
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patients with schizophrenia have impairments in the 
dorsolateral prefrontal cortex (DLPFC) and orbitofron-
tal cortex, which are involved in control, planning, and 
goal attainment [1]. Our results suggest that patients with 
schizophrenia who exhibit antisocial behavior or violence 
may have less DLPFC impairment than those without 
such behavior [3] as DLPFC is known for its involvement 
in working memory [34, 35] and executive function [36, 
37]. It is assumed that DLPFC activity is required to some 
extent to plan and commit violent or antisocial actions. 
In contrast, higher executive function in schizophrenia 
is related to both antipsychotic responsiveness, and a 
good prognosis for social function and employment [16], 
which are known protective factors against future vio-
lence risk [38]. It should be noted that the violent group 
patients in the present study were those who were con-
sidered to be treatment responsive. A more thorough 
investigation of the relationship between executive func-
tion and aggression, violent behavior, social function, and 
employment prognosis is needed.
This study has a number of limitations. A major limita-
tion is the low sample size with more importance placed 
on the low number of non-violent patients with sub-
stance abuse (only 3), as well as patients abusing different 
substances. Another major limitation is that the hospi-
talization durations in the control and violent groups 
were different. We recruited control subjects from the 
inpatient population of an ordinary psychiatric ward 
within the same hospital because our violent subjects 
were also inpatients. However, although no differences 
in PANSS scores or antipsychotic dosage were observed 
between the two groups, we were unable to eliminate 
the influence of duration of hospitalization and psycho-
social therapy, or other conditions on cognitive function. 
More specifically, the patients in the violent group gen-
erally had received a more enriched psychosocial treat-
ment program than the control group, which might have 
enhanced the cognitive function. Secondly, as already 
noted, the violent group patients in the present study 
were considered to be treatment responsive, which may 
have resulted in a better cognitive function in this group 
than the nonviolent group patients. In the future, stud-
ies assessing patient cognitive function before therapeu-
tic interventions are needed. In addition, the sample size 
was small because this study was conducted with patients 
in the MTSA ward of a single hospital and therefore, the 
findings should be taken as exploratory. Future research 
should be conducted in a multi-site design.
Conclusions
In summary, our results suggest that a certain group of 
patients with violent schizophrenia have characteris-
tic neuropsychological profiles. These findings can be 
used to support the development of more effective psy-
chosocial treatments and improve our understanding of 
patients with schizophrenia and a history of serious vio-
lent acts.
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